Therefore, we conducted this retrospective study to assess the efficacy of molecularly matched off‐label use of everolimus compared with conventional therapy in refractory breast cancer patients with active mutations in PI3K/ATK/mTOR pathway. This evidence concerns the gene BTK and breast carcinoma.